COSCIENS Biopharma Inc (CSCI): Price-to-Sales Ratio

The financial stability and pragmatism of COSCIENS Biopharma Inc. (CSCI) ensure shareholder confidence. On GURU.Markets, monitoring the company's P/S ratio demonstrates an impartial mathematical correlation between valuation and revenue, where 1.30 determines the current status of the parameter. While the Canadian-American management possesses deep expertise in endocrinology, low sales volumes and promotion costs currently limit margin growth.

CSCI: COSCIENS Biopharma Inc. P/S Multiple 08/10/2024 - 09/14/2025

Metric breakdowns and analytics for Aeterna Zentaris (CSCI)

- share price and consensus valuation forecast:

Price Performance Chart cosciensbio.com|CSCI - Price Target Chart

- stock exchange capitalization data:

Market Valuation Aeterna Zentaris|CSCI - Enterprise Value

- balance sheet net asset value indicators:

Accounting Value of a Share COSCIENS Biopharma|CSCI - Book Capitalization|Market Capitalization to Book Value Ratio cosciensbio.com|CSCI - Aggregate Company Assets

- debt obligations and liquidity statistics:

- earnings and valuation multiples information:

CSCI - Company Net Income|Company Profit Forecast COSCIENS Biopharma Inc.|CSCI - P/E Multiple|Projected Price to Earnings COSCIENS Biopharma Inc|CSCI - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Aeterna Zentaris|CSCI - Operating profit EBITDA|Net earnings per one share for the last twelve months COSCIENS Biopharma|CSCI - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months cosciensbio.com|CSCI - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year COSCIENS Biopharma Inc.

- issuer revenue and sales details:

CSCI - Company Sales|Company Future Revenue cosciensbio.com|CSCI - P/S Multiple|Price-to-Projected Revenue Ratio Aeterna Zentaris

General company analysis:CSCI cosciensbio.com

Finished products of COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc. (CSCI) is implementing robotic molecule screening and automated data digitization to accelerate drug development, rendering revenue a key marker for business scaling. This indicator, which divides the company's total value by annual income, determines the market premium per unit of sales; analyzing the price-to-sales ratio allows an investor to assess the asset's fundamental overvaluation and the risk of an impulsive entry.

Competing companies

VRTX (vrtx.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alnylam ALNY|INSM (Insmed Inc.) - Price-to-Sales Ratio|United Therapeutics Corp. - P/S Multiple|Market Capitalization-to-Revenue Ratio BMRN (BioMarin Corp)|BBIO: P/S Multiple|BGM Group (BGM) - P/S Multiple|Price-to-Revenue Ratio Cogent Biosciences, Inc.|XERS: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Keros Pharma (KROS)|Market Cap to Revenue Arcturus Corp ARCT|P/S Multiple ETON (Eton Pharmaceuticals)|P/S Multiple kamada.com KMDA|Fulcrum Therapeutics, Inc. - P/S Multiple|Abeona Therapeutics (ABEO) - Market Cap to Revenue|mereobiopharma.com (MREO) - Price-to-Revenue Ratio|Price to Sales Protalix BioTherapeutics, Inc (PLX)|Price-to-Revenue Ratio Pliant Therapeutics Inc|appliedtherapeutics.com (APLT) - Price-to-Revenue Coefficient|P/S Multiple RNTX|Market Cap to Revenue gelteq.com GELS|P/S Multiple AYTU (Aytu BioPharma)|Price-to-Revenue Coefficient Chemomab Therapeutics Ltd (CMMB)|SRx Health - P/S Multiple|Price to Sales Polyrizon Ltd|zentaris.com (AEZS) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio CYTH|Price-to-Revenue Ratio Inozyme Pharma Inc.|Reneo Pharmaceuticals, Inc (RPHM) - Price-to-Revenue Coefficient